A transatlantic technology collaboration has been brokered between protein engineering powerhouse Isogenica in Cambridge UK and Tucson-based Research Corporation Technologies, Inc. (RCT).

 The Arizona business will access Isogenica’s CIS display platform to screen proprietary libraries of a new antigen-binding protein scaffold.

RCT’s libraries are part of a biologics discovery platform to identify engineered antibody fragments called ABDURINS™ for development into therapeutic agents.

ABDURINS retain the desired long half-life of an antibody’s CH2 domain and are engineered for enhanced stability, epitope binding and other properties.

The partnership with Isogenica allows RCT to provide interested parties access to their proprietary, high throughput display and screening platform called CIS display.

CIS display can screen significantly larger libraries and isolate and optimise lead binders in a fraction of the time it takes using phage display.

Isogenica will also support RCT through deep sequencing and related bioinformatics tools that can inform the optimisation of the selected ABDURINS.

RCT believes the pairing of Isogenica’s CIS display with its ABDURIN platform will be an attractive offering to potential partners.

Isogenica’s CEO, Dr Kevin Matthews said: “Our agreement with RCT underlines the value that CIS display brings to companies that are pioneering new antibody scaffolds for the development of better medicines.

“We look forward to supporting the deployment of RCT’s library and working with their biopharma collaborators to find new therapeutic candidates.”